prognostic value of phosphohexose isomerase in childhood leukemia and lymphomas

ABSTRACT

Serum phosphohexose isomerase [P.H.I.] activity was measured in 12 children suffering from acute lymphoblastic leukemia [A.L.L.], 8 children having acute nonlymphoblastic leukemia [A.N.L.L.], 17 children suffering from non-Hodgkin's lymphoma [N.H.L.] and 20 aparently healthy children of comparable age and sex as controls. Significantly increased activity of P.H.I. was observed in children with leukemias and lymphomas compared to controls. Children with A.N.L.L. had significantly higher P.H.I. activity than those with A.L.L. Follow up of the children during various stages of therapy showed significant decrease of P.H.I. after induction of remission. The levels were evidently elevated again several months before clinical and/or hematological relapses. It could be concluded that P.H.I. can be helpful adjuvant marker in childhood leukemias and lymphomas. Also, it can of therapy and to detect the early relapse